Standard insulin therapy period
diabetes
EVENT, DIABETES
During the 8-week control therapy period, a glucose sensor (Dexcom G6) was worn by participants throughout the standard insulin therapy period. Sensor glucose on the sensor glucose receiver was masked to the participant and investigators until the end of the study. Participants continued their usual insulin therapy, and the study team did not make any alterations to participants’ medications. Other diabetes therapies were continued throughout the control therapy period. Fingerstick blood glucose monitoring was performed by participants as per their usual practice. Participants were unrestricted in their usual activities and dietary intake. Participants remained under the care of their local clinical team for glycemic management.Participants were given 24-h access to a study helpline in the event of any study-related issues. At the end of the standard insulin therapy period, the glucose sensor was removed and the usual insulin therapy of participants was continued.